NMIN researchers and colleagues have discovered a nanoparticle threshold dose that improves nanoparticle delivery and therapy for solid tumours. Published in Nature Materials, the study emerged from Dr. Warren Chan‘s Integrated Nanotechnology & Biomedical Sciences Laboratory at the University of Toronto, with NMIN researchers Drs. Chan and Gang Zheng as… Read More »NMIN researchers discover dose threshold for nanoparticle tumour delivery
In a new review article in Human Gene Therapy, NMIN researcher Dr. Colin Ross and NMIN HQP Tiffany Carlaw and Lin-Hua Zhang provide an overview of the current state of CRISPR/Cas9 base and prime editing technologies. “Therapeutic base editing is one form of genome engineering that has gained much interest… Read More »NMIN researchers discuss the current state of CRISPR/Cas9 editing
Using lipid nanoparticles (LNPs), NMIN research leaders Drs. Pieter Cullis and Christian Kastrup, together with colleagues at The University of British Columbia (UBC), have developed a new tool that can inhibit the activity of a blood protein involved in thrombosis and a number of other afflictions. The protein in question,… Read More »NMIN researchers: A new nanomedicine treatment for thrombosis?
The NanoMedicines Innovation Network (NMIN) is pleased to announce the third recipient of an NMIN-Mitacs Internship. In an internship of one year’s duration, Dr. Farahnaz Fathordoobady, NMIN HQP and Postdoctoral Fellow at the University of British Columbia (UBC), will collaborate with Ascension Sciences Inc. (ASI) to develop a novel oral… Read More »NMIN-Mitacs Intern developing novel cannabinoid delivery platforms
The NanoMedicines Innovation Network (NMIN) is pleased to announce the inaugural recipients of NMIN-Mitacs Internships: Drs. Kent Chen and Brian Hsu will both work with Cuprous Pharmaceuticals Inc. (CPI) on the development of novel nanomedicines to induce anticancer immunity, using CPI’s proprietary Metaplex technology. Dr. Kent Chen Dr. Brian Hsu… Read More »Inaugural NMIN-Mitacs Internships at Cuprous Pharmaceuticals Inc.
In a new review article published in Advanced Drug Delivery Reviews, NMIN researchers and colleagues discuss the use of state-of-the-art lipid nanoparticle (LNP) technology for therapeutic gene regulation in the liver. LNP technology enables the delivery of nucleic acids to treat liver diseases, addressing the root causes of these diseases… Read More »Lipid nanoparticle technology: poised to have a revolutionary impact
On March 31, 2020, NMIN’s Board of Directors approved a second round of research investment, supporting nine new projects—two within each of NMIN’s Research Themes (Targeted Drug Delivery, Gene Therapy, and Diagnostics), and three Strategic Initiatives. These new projects and initiatives, listed below by Research Theme, added 22 researchers and… Read More »Update: NMIN makes nine new research investments
NMIN Research Leader Dr. Shana Kelley discusses how new rapid diagnostic technologies could transform the way the COVID-19 pandemic is managed, in a webinar recorded on July 7, 2020. https://youtu.be/Zj4-N_CyuRg In the video, Dr. Kelley discusses innovative technologies being developed by researchers in her multidisciplinary PRiME group, including NMIN researcher… Read More »NMIN research leader discusses new diagnostic technology as key to “pandexit”
As of July 13, 2020, NMIN has a new Manager of Research and Partnerships: April O’Connell, BA, CHRP, CHRL. April brings eight years’ experience managing a multimillion-dollar research portfolio for AllerGen NCE. April was nationally recognized in 2019 for excellence in research management by the Canadian Association of Research Administrators… Read More »Meet April O’Connell, NMIN’s new Manager, Research & Partnerships
Two NMIN researchers based at the University of British Columbia (UBC) have been awarded CIHR funding to support projects addressing COVID19-related health challenges. NMIN’s Scientific Director, Dr. Pieter Cullis, was awarded $237,445 in support of his effort to develop an antibody therapy for COVID-19. The project, seed-funded by NMIN, will… Read More »NMIN researchers awarded CIHR funding for COVID-19 projects